Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
End stage liver disease is prone to thrombocytopenia. This study is a multi-center,
randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the
Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and
Thrombocytopenia.
Phase:
Phase 4
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Anhui Provincial Hospital Taihe Hospital, Hubei University of Medicine The First Affiliated Hospital of Nanchang University The First Hospital of Jilin University